Credit Suisse Ag Fulcrum Therapeutics, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$2.83 - $13.99 $23,324 - $115,305	8,242 Added 18.81%	52,062 $148,000
Q4 2022 Feb 13, 2023	BUY	$5.01 - $8.35 $106,362 - $177,270	21,230 Added 93.98%	43,820 $319,000
Q3 2022 Nov 10, 2022	BUY	$4.92 - $9.1 $6,538 - $12,093	1,329 Added 6.25%	22,590 $183,000
Q2 2022 Aug 12, 2022	BUY	$4.2 - $24.0 $13,041 - $74,520	3,105 Added 17.1%	21,261 $104,000
Q1 2022 May 16, 2022	SELL	$9.96 - $23.65 $5,936 - $14,095	-596 Reduced 3.18%	18,156 $429,000
Q4 2021 Feb 14, 2022	BUY	$14.0 - $28.44 $262,528 - $533,306	18,752 New	18,752 $332,000

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $237M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.